Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T8954 |
ML179
ML-179 |
Others | Others |
ML179 是一种有效的选择性肝受体同源物 1 (LRH1, NR5A2) 反向激动剂,IC50 为 320 nM。 | |||
T1785 |
Palbociclib
PD 0332991,帕博西尼,帕布昔利布 |
CDK | Cell Cycle/Checkpoint |
Palbociclib (PD 0332991) 是一种 CDK 抑制剂,抑制 CDK4 和 CDK6 (IC50=11/16 nM),具有口服活性。Palbociclib 具有抗肿瘤活性,有用于 ER 阳性和 HER2 阴性乳腺癌的研究潜力。 | |||
T70686 |
HJC-0123
|
||
Downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values. Furthermore, HJC-0123 significantly suppressed estrogen receptor (ER)-negative breast cancer MDA-MB-231 xenograft tumor growth in vivo (p.o.), indicating its great potential as an efficacious and orally bioavailable drug candidate for human cancer therapy. | |||
T61923 |
ERRα antagonist-2
|
||
ERRα antagonist-2 (Compound 11) 是潜在的ERRα (雌激素受体相关受体 α)反向激动剂(IC50= 0.80 μM)。ERRα antagonist-2 对 ER 阴性 MDA-MB-231 细胞的迁移和侵袭具有抑制作用。ERRα antagonist-2 抑制体内乳腺癌的生长。 |